<?xml version='1.0' encoding='utf-8'?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://isthisbs.org/health/in-the-phase-3-surmount-1-trial-participants-received-once-5-ebfbcb58/</loc><news:news><news:publication><news:name>IsThisBS</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T14:50:12.186820+00:00</news:publication_date><news:title>SURMOUNT-1 tested three once-weekly subcutaneous tirzepatide target doses against placebo over 72 weeks.</news:title></news:news></url><url><loc>https://isthisbs.org/health/at-week-72-of-the-phase-3-surmount-1-trial-the-mean-change-9-2488ed49/</loc><news:news><news:publication><news:name>IsThisBS</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T14:49:19.525862+00:00</news:publication_date><news:title>Once-weekly 5 mg tirzepatide produced −15.0% mean weight change at week 72.</news:title></news:news></url><url><loc>https://isthisbs.org/health/the-phase-3-surmount-1-trial-enrolled-2539-adults-without-a-2b4a97b3/</loc><news:news><news:publication><news:name>IsThisBS</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T14:47:05.728532+00:00</news:publication_date><news:title>Phase 3 SURMOUNT-1 enrolled 2,539 adults without diabetes under the stated BMI criteria.</news:title></news:news></url></urlset>